{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:16:03Z","timestamp":1780568163512,"version":"3.54.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.beha.2017.08.001","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T21:01:33Z","timestamp":1501794093000},"page":"184-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: Current treatment and novel therapies"],"prefix":"10.1016","volume":"30","author":[{"given":"Kristen M.","family":"O'Dwyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L.","family":"Liesveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2017.08.001_bib1","unstructured":"SEER Cancer Statistics Factsheets: Acute Lymphocytic Leukemia. National Cancer Institute. Bethesda, MD, http:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html"},{"issue":"13","key":"10.1016\/j.beha.2017.08.001_bib2","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2016-11-749507","article-title":"Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis","volume":"129","author":"Geyer","year":"2017","journal-title":"Blood"},{"issue":"4 Suppl 2","key":"10.1016\/j.beha.2017.08.001_bib3","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminoncol.2009.05.002","article-title":"Central nervous system disease in hematologic malignancies: historical perspective and practical applications","volume":"36","author":"Pui","year":"2009","journal-title":"Semin Oncol"},{"key":"10.1016\/j.beha.2017.08.001_bib4","first-page":"3903","article-title":"Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US intergroup trial C10403 (alliance)","author":"Advani","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2017.08.001_bib5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/asheducation-2016.1.573","article-title":"Treatment of older patients with acute lymphoblastic leukemia","volume":"2016","author":"Gokbuget","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"8","key":"10.1016\/j.beha.2017.08.001_bib6","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/cncr.23819","article-title":"Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia","volume":"113","author":"O'Brien","year":"2008","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.beha.2017.08.001_bib7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","article-title":"Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial","volume":"157","author":"Sive","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.beha.2017.08.001_bib8","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","article-title":"Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2017.08.001_bib9","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A\u00a0five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2017.08.001_bib10","first-page":"1556","article-title":"A\u00a0randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111","volume":"92","author":"Larson","year":"1998","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2017.08.001_bib11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.27617","article-title":"Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802","volume":"119","author":"Stock","year":"2013","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.beha.2017.08.001_bib12","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.08.001_bib13","volume":"120","author":"Gokbuget","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.08.001_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.leukres.2015.11.012","article-title":"Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: results of three prospective parallel trials from the PETHEMA group","volume":"41","author":"Ribera","year":"2016","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.beha.2017.08.001_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.beha.2017.08.001_bib16","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2017.08.001_bib17","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.2732.2732","article-title":"Subtype adjusted therapy improves outcome of elderly patients with acute lymphoblastic leukemia (ALL)","volume":"104","author":"Hoelzer","year":"2004","journal-title":"Blood"},{"issue":"588","key":"10.1016\/j.beha.2017.08.001_bib18","article-title":"Inotuzumab Ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia (ALL): interim result of a phase II clinical trial","volume":"128","author":"Sasaki","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2017.08.001_bib19","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1 Suppl 2","key":"10.1016\/j.beha.2017.08.001_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2017.08.001_bib21","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3324\/haematol.2009.010306","article-title":"Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"95","author":"Maury","year":"2010","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.beha.2017.08.001_bib22","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-Lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.beha.2017.08.001_bib23","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2010.27.9836","article-title":"Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies","volume":"28","author":"Cheson","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2017.08.001_bib24","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J\u00a0Immunol"},{"issue":"15","key":"10.1016\/j.beha.2017.08.001_bib25","doi-asserted-by":"crossref","first-page":"7065","DOI":"10.1200\/jco.2014.32.15_suppl.7065","article-title":"Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive ALL","volume":"32","author":"Jabbour","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.beha.2017.08.001_bib26","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2174\/1381612003398564","article-title":"Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research","volume":"6","author":"Thorson","year":"2000","journal-title":"Curr Pharm Des"},{"issue":"6","key":"10.1016\/j.beha.2017.08.001_bib27","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.beha.2017.08.001_bib28","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.beha.2017.08.001_bib29","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00280-010-1342-9","article-title":"Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP","volume":"67","author":"DiJoseph","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.beha.2017.08.001_bib30","unstructured":"Amgen Inc TO, CA, USA."},{"issue":"18","key":"10.1016\/j.beha.2017.08.001_bib31","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.beha.2017.08.001_bib32","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.beha.2017.08.001_bib33","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/cncr.30031","article-title":"Blinatumomab treatment of older adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies","volume":"122","author":"Kantarjian","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.beha.2017.08.001_bib34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2005-11-4666","article-title":"Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII\/ECOG E2993","volume":"108","author":"Lazarus","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2017.08.001_bib35","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.1993.11.10.1990","article-title":"Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia","volume":"11","author":"Fiere","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2017.08.001_bib36","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2017.08.001_bib37","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/sj.leu.2402006","article-title":"Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate\/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study","volume":"15","author":"Petersdorf","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2017.08.001_bib38","first-page":"1","article-title":"Managing CNS disease in adults with acute lymphoblastic leukemia","author":"Larson","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"3\u20134","key":"10.1016\/j.beha.2017.08.001_bib39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/10428199609051761","article-title":"Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia","volume":"22","author":"Bassan","year":"1996","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.beha.2017.08.001_bib40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/10428190400019917","article-title":"Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL)","volume":"46","author":"Offidani","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.beha.2017.08.001_bib41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1600-0609.1990.tb00424.x","article-title":"Acute lymphoblastic leukemia in the elderly","volume":"45","author":"Delannoy","year":"1990","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2017.08.001_bib42","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3324\/haematol.2010.027862","article-title":"A\u00a0randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study","volume":"96","author":"Hunault-Berger","year":"2011","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.beha.2017.08.001_bib43","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1002\/cncr.30037","article-title":"Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia","volume":"122","author":"Fathi","year":"2016","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.beha.2017.08.001_bib44","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1046\/j.1365-2141.1997.952909.x","article-title":"Prognostic factors in elderly acute lymphoblastic leukaemia","volume":"97","author":"Legrand","year":"1997","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2017.08.001_bib45","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/bjh.12561","article-title":"Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol","volume":"163","author":"Martell","year":"2013","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.beha.2017.08.001_bib46","first-page":"1327","article-title":"Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study","volume":"85","author":"Pagano","year":"2000","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2017.08.001_bib47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3143\/geriatrics.36.52","article-title":"Analysis of elderly patients, aged 60 years old or over, with acute lymphoblastic leukemia","volume":"36","author":"Nagura","year":"1999","journal-title":"Nihon Ronen Igakkai Zasshi"},{"issue":"4","key":"10.1016\/j.beha.2017.08.001_bib48","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00277-003-0808-9","article-title":"Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experience","volume":"83","author":"Robak","year":"2004","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.beha.2017.08.001_bib49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF01696557","article-title":"Acute lymphoblastic leukemia in patients over 59 years of age. Experience in a single center over a 10-year period","volume":"69","author":"Spath-Schwalbe","year":"1994","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.beha.2017.08.001_bib50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ajh.1083","article-title":"Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience","volume":"67","author":"Thomas","year":"2001","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.beha.2017.08.001_bib51","first-page":"1643","article-title":"Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period","volume":"9","author":"Ferrari","year":"1995","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2017.08.001_bib52","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood.V80.7.1813.1813","article-title":"Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome","volume":"80","author":"Taylor","year":"1992","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2017.08.001_bib53","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2009-07-232124","article-title":"A\u00a0population-based cytogenetic study of adults with acute lymphoblastic leukemia","volume":"115","author":"Moorman","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2017.08.001_bib54","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2010-03-272724","article-title":"Population-based analyses in adult acute lymphoblastic leukemia","volume":"116","author":"Juliusson","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2017.08.001_bib55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2141.2011.09020.x","article-title":"Adult acute lymphoblastic leukaemia in Denmark. A national population-based retrospective study on acute lymphoblastic leukaemia in Denmark 1998-2008","volume":"157","author":"Toft","year":"2012","journal-title":"Br J Haematol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T05:06:17Z","timestamp":1602651977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692617300282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1521692617300282"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2017.08.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: Current treatment and novel therapies","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2017.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}